Published in Cancer Weekly, February 2nd, 2010
"More recently, immune-modulatory approaches, including the use of T-cell checkpoint inhibitors or agents that can affect T-cell or antigen-presenting cell function, have been studied. Most clinical trials with individual immune...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-02-02)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.